8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Gilead raises 2026 revenue outlook after third-quarter sales growth
Filed with the SEC on · Summarized by InvestorsBot
Gilead reported third-quarter 2026 product sales of $8.3 billion, up 13% year over year, while non-GAAP diluted EPS rose to $2.55 from $2.47; HIV sales increased 18% to $6.2 billion, led by Biktarvy sales of $4.1 billion. The company raised full-year product sales guidance to $31.0 billion-$31.3 billion from $30.1 billion-$30.4 billion, but now expects GAAP diluted losses of $4.40-$4.05 per share, largely reflecting $12.4 billion of acquired in-process research and development charges tied to acquisitions.